Haojie Zhu is an Associate Professor in the Department of Clinical Pharmacy, University of Michigan College of Pharmacy. He graduated from the China Pharmaceutical University with a major in Pharmacy, and further received his M.S. and Ph.D. in Pharmacology from the same University. He also holds a MBA degree from Nanjing University. He was a licensed Pharmacist as well as a trained Dentist in China. Dr. Zhu completed his post-doctoral training in Pharmacogenomics, Pharmacokinetics, and Neuropsychopharmacology at the Medical University of South Carolina. His research focuses on identifying both genetic variations and environmental factors that impact pharmacokinetics and pharmacodynamics of various therapeutic agents, and using the information to guide the personalized use of medications in order to maximize efficacy while minimizing the risk of adverse effects. Additionally, the drug transporters expressed within the central nervous system are also among his major research interests.  

Research Interests

  • Utilize a combined approach of pharmacogenomics, proteomics, and metabonomics to identify biomarkers associated with interindividual variability of pharmacotherapy, and apply these biomarkers to the practice of Personalized Medicine

  • Elucidate the role of uptake-2 transporters in the maintenance of neurotransmitter homeostasis, and evaluate these transporters as a potential drug target for neuropsychiatric disorders


  • 2016 JBC/Herbert Tabor Young Investigator Award, The Journal of Biological Chemistry
  • 2015 AACP New Investigator Award , American Association of Colleges of Pharmacy (AACP)

Selected Publications

  • Wang X, Rida N, Shi J, Wu A, Bleske B, Zhu HJ. A comprehensive functional assessment of carboxylesterase 1 nonsynonymous polymorphisms. Drug Metab Dispos. 2017 Aug 24. pii: dmd.117.077669. doi: 10.1124/dmd.117.077669. PMID: 28838926


    Zhu HJ, Patrick KS, Straughn AB, Reeves OT 3rd, Bernstein H, Shi J, Johnson HJ, Knight JM, Smith AT, Malcolm RJ, Markowitz JS. Ethanol Interactions With Dexmethylphenidate and dl-Methylphenidate Spheroidal Oral Drug Absorption Systems in Healthy Volunteers. J Clin Psychopharmacol. 2017 Aug;37(4):419-428. doi: 10.1097/JCP.0000000000000721. PMID: 28590363


    Shi J, Wang X, Nguyen JH, Bleske BE, Liang Y, Liu L, Zhu HJ. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender. Biochem Pharmacol. 2016 Sep 8. pii: S0006-2952(16)30263-5. doi: 10.1016/j.bcp.2016.09.003. PMID: 27614009


    Zhu HJ, Langaee TY, Gong Y, Wang X, Pepine CJ, Cooper-DeHoff RM, Johnson JA, Markowitz JS. CES1P1 variant -816A>C is not associated with hepatic carboxylesterase 1 expression and activity or antihypertensive effect of trandolapril. Eur J Clin Pharmacol. 2016 Jun;72(6):681-7. doi: 10.1007/s00228-016-2029-x. Epub 2016 Feb 26. PMID: 26915813


    Wang X, Liang Y, Liu L, Shi J, Zhu HJ. Targeted absolute quantitative proteomics with SILAC internal standards and unlabeled full-length protein calibrators (TAQSI). Rapid Commun Mass Spectrom. 2016 Mar 15;30(5):553-61. doi: 10.1002/rcm.7482. PMID: 26842578


    Shi J, Wang X, Nguyen J, Wu AH, Bleske BE, Zhu HJ. Sacubitril Is Selectively Activated by Carboxylesterase 1 (CES1) in the Liver and the Activation Is Affected by CES1 Genetic Variation. Drug Metab Dispos. 2016 Apr;44(4):554-9. doi: 10.1124/dmd.115.068536. Epub 2016 Jan 27. PMID: 26817948


    Wang X, Wang G, Shi J, Aa J, Comas R, Liang Y, Zhu HJ. CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors. Pharmacogenomics J. 2016 Jun;16(3):220-30. doi: 10.1038/tpj.2015.42. Epub 2015 Jun 16. PMID: 26076923